<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02713477</url>
  </required_header>
  <id_info>
    <org_study_id>PDY14115</org_study_id>
    <secondary_id>U1111-1176-6235</secondary_id>
    <nct_id>NCT02713477</nct_id>
  </id_info>
  <brief_title>Postprandial Glucodynamic Response to Insulin Glargine/Lixisenatide Fixed Ratio Combination in Japanese Patients With Type 2 Diabetes Mellitus</brief_title>
  <official_title>A Randomized, Open Label, Placebo-controlled, 4-sequence, 4-period, 4-treatment Crossover Study to Investigate the Postprandial Glucodynamic Response to Single Dose of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Japanese Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      To assess the postprandial glucodynamic response to 2 doses of insulin glargine/lixisenatide
      fixed-ratio combination compared to placebo in Japanese patients with type 2 diabetes
      mellitus (T2DM).

      Secondary Objectives:

        -  To assess the pharmacokinetics (PK) of lixisenatide following administration of 2
           different doses of insulin glargine/lixisenatide fixed-ratio combination in Japanese
           patients with T2DM.

        -  To assess the postprandial glucodynamic response to insulin glargine/lixisenatide
           fixed-ratio combination compared to insulin glargine alone in Japanese patients with
           T2DM.

        -  To assess the safety and tolerability of insulin glargine/lixisenatide fixed-ratio
           combination in Japanese patients with T2DM.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The total study duration per patient will be approximately 6 to 13 weeks that will consist of
      a 2-28 days of screening period, a 3-day treatment period, a 7-14 days of washout period, and
      1-day end of study visit.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of plasma glucose concentrations</measure>
    <time_frame>1 day (D1) in each treatment period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measurement of serum insulin concentrations</measure>
    <time_frame>1 day (D1) in each treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of serum C-peptide concentrations</measure>
    <time_frame>1 day (D1) in each treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of plasma glucagon concentrations</measure>
    <time_frame>1 day (D1) in each treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of plasma lixisenatide concentrations</measure>
    <time_frame>1 day (D1) in each treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with hypoglycemic events</measure>
    <time_frame>Up to 2 weeks after each treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>Up to 2 weeks after each treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of anti-lixisenatide antibodies</measure>
    <time_frame>2 days (prior to first dosing and end of study visit)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of anti-insulin antibodies</measure>
    <time_frame>2 days (prior to first dosing and end of study visit)</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Insulin glargine/ lixisenatide dose 1 Test 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Test 1 will be administered thru subcutaneous (SC) injection into one peri-umbilical site of the abdomen 1 hour prior to breakfast under fasted condition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin glargine/ lixisenatide dose 2 Test 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Test 2 will be administered thru SC injection into one peri-umbilical site of the abdomen 1 hour prior to breakfast under fasted condition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - Reference 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Reference 1 will be administered thru SC injection into one peri-umbilical site of the abdomen 1 hour prior to breakfast under fasted condition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin glargine (Lantus) - Reference 2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Reference 2 will be administered thru SC injection into one peri-umbilical site of the abdomen 1 hour pior to breakfast under fasted condition</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin glargine/ lixisenatide fixed-ratio combination HOE901/AVE0010</intervention_name>
    <description>Pharmaceutical form: solution
Route of administration: subcutaneous</description>
    <arm_group_label>Insulin glargine/ lixisenatide dose 1 Test 1</arm_group_label>
    <arm_group_label>Insulin glargine/ lixisenatide dose 2 Test 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin glargine HOE901</intervention_name>
    <description>Pharmaceutical form: solution
Route of administration: subcutaneous</description>
    <arm_group_label>Insulin glargine (Lantus) - Reference 2</arm_group_label>
    <other_name>Lantus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Pharmaceutical form: solution
Route of administration: subcutaneous</description>
    <arm_group_label>Placebo - Reference 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :

          -  Japanese male or female patients with T2DM diagnosed for at least 1 year prior to the
             time of screening as established in the medical history.

          -  Patients aged 20 to 75 years at screening.

          -  Body mass index ≤35 kg/m^2 at screening.

          -  Glycohemoglobin ≥7.0% and ≤10.0% at screening.

          -  Fasting C-peptide ≥0.6 ng/mL at screening.

        Exclusion criteria:

          -  Diabetes other than T2DM.

          -  History of metabolic acidosis, including diabetic ketoacidosis within 1 year prior to
             screening.

          -  History of hypoglycemia unawareness.

          -  Hemoglobinopathy or hemolytic anemia.

          -  History of myocardial infarction, stroke, or heart failure, history or presence of
             clinically significant diabetic retinopathy, history or presence of macular edema
             likely to require laser treatment within the study period.

          -  History of unexplained pancreatitis, chronic pancreatitis, pancreatectomy,
             stomach/gastric surgery, inflammatory bowel disease.

          -  Clinically relevant history of gastrointestinal disease associated with prolonged
             nausea and vomiting, including, but not limited to gastroparesis and gastroesophageal
             reflux disease requiring medical treatment.

          -  Personal or family history of medullary thyroid cancer (MTC) or genetic conditions
             that predispose to MTC (e.g., multiple endocrine neoplasia syndromes).

          -  If female, pregnancy or breast-feeding.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 392001</name>
      <address>
        <city>Fukuoka-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2016</study_first_submitted>
  <study_first_submitted_qc>March 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2016</study_first_posted>
  <last_update_submitted>June 28, 2016</last_update_submitted>
  <last_update_submitted_qc>June 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Lixisenatide</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

